| dataset_desc |
The ACC/AHA Joint Committee on Clinical Practice G The ACC/AHA Joint Committee on Clinical Practice Guidelines has commissioned this guideline to
focus on the diagnosis and management of adult patients with valvular heart disease (VHD). The
guideline recommends a combination of lifestyle modifications and medications that constitute
components of GDMT. For both GDMT and other recommended drug treatment regimens, the
reader is advised to confirm dosages with product insert material and to carefully evaluate for
contraindications and drug–drug interactions.
The following resource contains tables and figures from the 2020 Guideline for the Management
of Patients With Valvular Heart Disease. The resource is only an excerpt from the Guideline and
the full publication should be reviewed for more tables and figures as well as important context.
Disease stages in patients with valvular heart disease should be classified (Stages A, B, C, and D) on the
basis of symptoms, valve anatomy, the severity of valve dysfunction, and the response of the ventricle and pulmonary circulation.
In the evaluation of a patient with valvular heart disease, history and physical examination findings should
be correlated with the results of noninvasive testing (i.e., ECG, chest x-ray, transthoracic echocardiogram).
If there is discordance between the physical examination and initial noninvasive testing, consider further noninvasive
(computed tomography, cardiac magnetic resonance imaging, stress testing) or invasive (transesophageal
echocardiography, cardiac catheterization) testing to determine optimal treatment strategy.
For patients with valvular heart disease and atrial fibrillation (except for patients with rheumatic mitral stenosis or a
mechanical prosthesis), the decision to use oral anticoagulation to prevent thromboembolic events, with either
a vitamin K antagonist or a non–vitamin K antagonist anticoagulant, should be made in a shared decision-making process
based on the CHA2DS2-VASc score. Patients with rheumatic mitral stenosis or a mechanical prosthesis and atrial fibrillation
should have oral anticoagulation with a vitamin K antagonist
All patients with severe valvular heart disease being considered for valve intervention should be evaluated by a
multidisciplinary team, with either referral to or consultation with a Primary or Comprehensive Valve Center
Treatment of severe aortic stenosis with either a transcatheter or surgical valve prosthesis should be based
primarily on symptoms or reduced ventricular systolic function. Earlier intervention may be considered if
indicated by results of exercise testing, biomarkers, rapid progression, or the presence of very severe stenosis.
Indications for transcatheter aortic valve implantation are expanding as a result of multiple randomized trials of
transcatheter aortic valve implantation versus surgical aortic valve replacement. The choice of type of intervention
for a patient with severe aortic stenosis should be a shared decision-making process that considers the lifetime risks and
benefits associated with type of valve (mechanical versus bioprosthetic) and type of approach (transcatheter versus surgical).
Indications for intervention for valvular regurgitation are relief of symptoms and prevention of the irreversible
long-term consequences of left ventricular volume overload. Thresholds for intervention now are lower than they
were previously because of more durable treatment options and lower procedural risks.
A mitral transcatheter edge-to-edge repair is of benefit to patients with severely symptomatic primary
mitral regurgitation who are at high or prohibitive risk for surgery, as well as to a select subset of patients
with secondary mitral regurgitation who remain severely symptomatic despite guideline-directed management and
therapy for heart failure
Patients presenting with severe symptomatic isolated tricuspid regurgitation, commonly associated with
device leads and atrial fibrillation, may benefit from surgical intervention to reduce symptoms and recurrent
hospitalizations if done before the onset of severe right ventricular dysfunction or end-organ damage to the liver and kidney
Bioprosthetic valve dysfunction may occur because of either degeneration of the valve leaflets or valve
thrombosis. Catheter-based treatment for prosthetic valve dysfunction is reasonable in selected patients for
bioprosthetic leaflet degeneration or paravalvular leak in the absence of active infection
WHAT IS NEW IN AORTIC STENOSIS
Major Changes in Valvular Heart Disease Guideline Recommendations
Noncardiac
conditions?
Frailty?.
Estimated
procedural or
surgical risk of
SAVR or TAVI?
Procedure-specific
impediments?
Goals of Care
and patient
preferences and
values?
Timing of intervention for AS
Choice of SAVR versus TAVI when AVR is indicated for valvular AS.
Stages of Aortic Stenosis
D: Symptomatic severe AS
WHAT IS NEW IN MITRAL REGURGITATION
Secondary MR.
Stages of Secondary MR.
WHAT IS NEW IN ANTICOAGULATION
Anticoagulation for AF in Patients With VHD.
... |